About Fluxion Biosciences
Fluxion Biosciences produces automated patch clamp technology and cell-based assay tools. Its products include ERASE-Seq for next-generation sequencing (NGS) analysis of cancer from a "liquid biopsy" blood sample, IsoFlux for circulating tumor cell analysis, and more. It was founded in 2005 and is based in Oakland, California. In August 2023, Fluxion Biosciences was acquired by Cell Microsystems. The terms of the transaction were not disclosed.
Fluxion Biosciences Patents
Fluxion Biosciences has filed 7 patents.
Molecular biology, Genetics, Biotechnology, DNA, Transcription factors
Molecular biology, Genetics, Biotechnology, DNA, Transcription factors
Latest Fluxion Biosciences News
Nov 4, 2023
Search jobs 02-Nov-2023 Liquid Biopsy Market to Observe Prominent CAGR of 15.2% by 2030, Size, Share, Trends, Demand, Growth, Challenges and Competitive Outlook Data Bridge Market research has recently published the comprehensive business research on Liquid Biopsy Market includes historic data, present market trends, future product environment, marketing strategies, technological innovation, upcoming technologies, emerging trends or opportunities, and the technical progress in the related industry. Liquid liquid Market analysis report covers detailed value chain analysis of the market. Data Bridge Market Research analyzes that the global liquid biopsy market will grow at a CAGR of 15.2% during the forecast period of 2023 to 2030. The global liquid biopsy market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in the developmental activity for launching novel services in the market. The increasing development in the field of advanced healthcare techniques is further boosting market growth. However, difficulties such as the lack of standardized protocols and the lack of skilled professionals might hamper the growth of the global liquid biopsy market in the forecast period. Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @ A liquid biopsy is a medical test that involves the analysis of various biomolecules, such as DNA, RNA, proteins, and other substances in a patient’s blood or other bodily fluids, to diagnose and monitor various medical conditions, including cancer. Unlike traditional biopsies that involve the removal of tissue samples from the body, a liquid biopsy is non-invasive and can provide important diagnostic information without the need for surgery or other invasive procedures. Liquid biopsies are still in the early stages of development but hold promise for improving the detection and management of cancer and other diseases. Global Liquid Biopsy Market Scope The global liquid biopsy market is categorized into nine notable segments which are product, Biomaker type, sample type, analytical type, application type, clinical application, technology, end user, and distribution channel. The growth amongst these segments will help you analyze market growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications. Product Others On the basis of distribution channel, the market is segmented into direct tender, third party distributor, and others. Access Full 350 Pages PDF Report @ Some of the major players in the global liquid biopsy market are F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., Exact Sciences Corporation (Genomic health), QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, mdxhealth, NeoGenomics Laboratories, Bio-Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC., PathAI, STRECK, Menarini Silicon Biosystems, Biocept, Inc., Sysmex Inostics Inc., Fluxion Biosciences Inc, Epic Sciences, Predicine, ANGLE plc, and Oncocyte Corporation among others. The report provides insights on the following pointers: Market Penetration: Comprehensive information on the product portfolios of the top players in the Liquid Biopsy Market. Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market. Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market. Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Liquid Biopsy Market. Table of Content: North America [U.S., Canada, Mexico] Europe [Germany, UK, France, Italy, Rest of Europe] Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific] South America [Brazil, Argentina, Rest of Latin America] The Middle East & Africa [GCC, North Africa, South Africa, Rest of the Middle East and Africa] This study answers to the below key questions: What are the key factors driving the Liquid Biopsy Market? What are the challenges to market growth? Who are the key players in the Liquid Biopsy Market? What are the market opportunities and threats faced by the key players? Browse Trending Reports:
Fluxion Biosciences Frequently Asked Questions (FAQ)
When was Fluxion Biosciences founded?
Fluxion Biosciences was founded in 2005.
Where is Fluxion Biosciences's headquarters?
Fluxion Biosciences's headquarters is located at 1901 Poplar Street, Oakland.
What is Fluxion Biosciences's latest funding round?
Fluxion Biosciences's latest funding round is Acquired.
How much did Fluxion Biosciences raise?
Fluxion Biosciences raised a total of $15.9M.
Who are the investors of Fluxion Biosciences?
Investors of Fluxion Biosciences include Cell Microsystems, Paycheck Protection Program, National Cancer Institute, Life Science Angels, Claremont Creek Ventures and 4 more.
Who are Fluxion Biosciences's competitors?
Competitors of Fluxion Biosciences include Parithera, Sword Bio, Cellix, Gentronix Limited, BioNano Genomics and 7 more.
Compare Fluxion Biosciences to Competitors
Sword Bio develops a medical data research platform designed to determine and monitor the value of biological markers. The platform uses a technology involving resonance Raman to aid in the performance of the assays offering medical research, drug discovery, and the provision of healthcare products and services. It was formerly known as Sword Diagnostics. The company was founded in 2004 and is based in Chicago, Illinois.
The scientists at Genomic Solutions have a wealth of genomic, protein analysis and nano-liter dispensing application-based expertise that they would like to share with users. First select their area of research, followed by interest and then application, and finally, to the company's instrumentation which can help facilitate their research. Whether users are involved in the life science or biotechnology research community, the company's products will enable users to perform complex, high volume experiments at a lower cost and in less time than traditional techniques. You achieve rapid and less expensive drug discovery.
Gentronix provides toxicology testing services for pharmaceuticals, agrochemicals, cosmetics, personal care and consumer products. The company enables major global brands to perform hazard and safety assessments, from early-stage discovery through to regulatory submission and approval.
Promega is a company focused on biochemistry and molecular biology within the life sciences industry. The company offers innovative, high-value products for the life sciences, including biological reagents and reagent systems used in research and applied technology applications. Promega primarily serves the life sciences research sector. It was founded in 1978 and is based in Madison, Washington.
Echelon Biosciences is a company that focuses on biochemical reagents, assays, and peptides within the academic research and pharmaceutical development sectors. The company offers a range of products and services including antibodies, proteins, biochemical reagents, and custom synthesis services, all designed to support scientific research and development. Echelon Biosciences primarily serves the academic research and pharmaceutical development industries. It is based in Salt Lake City, Utah.
Integromics aims to provide bioinformatics software solutions for data management and data analysis in genomics, proteomics and drug discovery. The company's software technology aims to enhance the ability to effectively organize data, perform validated analyses, discover new biomedical knowledge and gain well-founded insights.